These results correlated with recent in vitro and in vivo clinical data, where bone marrow-derived macrophage efferocytosis of cancer cells promotes the expression of CCL5, CXCL1, CXCL5, and IL-6 pro-inflammatory cytokines that accelerate tumor progression in the bone microenvironment [7]. This evidence concerns the gene CXCL1 and neoplasm.